13 Investor presentation First nine months of 2021 R&D milestones F Project Q Diabetes care Ozempic ® Obesity care Biopharm FDC Sema – OW GIP Cagrisema T2DM Glucose sensitive insulin IcoSema Icodec Ideal Pump Insulin Semaglutide 2.4 mg Oral sema 50 mg PYY1875 CagriSema LA-GDF15 Sogroya ® (somapacitan) ✓ Pha ✓ Ph ✓ Pha ✓ Phase Mim8 Other serious chronic diseases Concizumab FGF21 NASH Sema NASH ✓ Pha ✓ Phas NASH – combination with Gilead ✓ Pha Ziltivekimab ✓ Pha 1 Expected to be published in the given quarter or in the subsequent quarterly company announcement, 2 GHD includes growth hormone in children, tria 3 First patient first visit expected for Q4 2021, which is solely for baselining purpose. Trial is started at risk since Phase 1/2 not completed Note: Trial initiations could be impacted by COVID-19, NASH: Non-alcoholic steatohepatitis; (A)GHD: (Adult) Growth Hormone Deficiency; Sema: Semagluti Note: The timelines for ideal pump insulin and LA-GDP15 have moved. Besides above milestones, semaglutide 2.4mg was submitted in Japan in Q3
Download PDF file